Adit Ginde
Concepts (552)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Emergency Service, Hospital | 82 | 2023 | 1864 | 9.470 |
Why?
| Sepsis | 18 | 2023 | 531 | 4.160 |
Why?
| Outpatients | 12 | 2023 | 325 | 4.090 |
Why?
| Critical Illness | 18 | 2023 | 662 | 4.000 |
Why?
| Vitamin D | 19 | 2021 | 354 | 3.360 |
Why?
| Vitamin D Deficiency | 14 | 2021 | 162 | 3.130 |
Why?
| Hospitalization | 39 | 2023 | 1784 | 2.840 |
Why?
| Cholecalciferol | 6 | 2021 | 51 | 2.460 |
Why?
| Hyperoxia | 4 | 2023 | 97 | 2.430 |
Why?
| Emergency Medicine | 13 | 2023 | 238 | 2.420 |
Why?
| Physician Assistants | 7 | 2014 | 68 | 2.420 |
Why?
| Patient Discharge | 11 | 2022 | 794 | 2.390 |
Why?
| Length of Stay | 20 | 2021 | 1031 | 2.380 |
Why?
| Adult | 132 | 2023 | 31510 | 2.290 |
Why?
| Hospital Mortality | 17 | 2023 | 814 | 2.250 |
Why?
| Humans | 244 | 2023 | 118969 | 2.230 |
Why?
| Emergency Medical Services | 13 | 2023 | 589 | 2.210 |
Why?
| Respiration, Artificial | 10 | 2023 | 545 | 2.090 |
Why?
| United States | 84 | 2023 | 12554 | 2.070 |
Why?
| Aged | 85 | 2023 | 19656 | 1.960 |
Why?
| Ritonavir | 3 | 2023 | 70 | 1.940 |
Why?
| Hospitals | 9 | 2023 | 597 | 1.870 |
Why?
| Patient Transfer | 5 | 2015 | 143 | 1.840 |
Why?
| Middle Aged | 104 | 2023 | 27617 | 1.840 |
Why?
| Wounds and Injuries | 6 | 2022 | 772 | 1.810 |
Why?
| Laryngoscopy | 7 | 2023 | 97 | 1.790 |
Why?
| Respiratory Tract Infections | 7 | 2021 | 331 | 1.770 |
Why?
| Health Services Accessibility | 11 | 2019 | 781 | 1.740 |
Why?
| Male | 130 | 2023 | 57800 | 1.600 |
Why?
| Oxygen | 8 | 2023 | 854 | 1.580 |
Why?
| Patient Readmission | 5 | 2022 | 633 | 1.540 |
Why?
| Cross-Sectional Studies | 34 | 2023 | 4552 | 1.500 |
Why?
| Influenza, Human | 9 | 2023 | 554 | 1.450 |
Why?
| Female | 127 | 2023 | 61564 | 1.440 |
Why?
| Patient Admission | 7 | 2017 | 176 | 1.350 |
Why?
| Nursing Homes | 3 | 2015 | 130 | 1.340 |
Why?
| Laryngoscopes | 6 | 2023 | 38 | 1.320 |
Why?
| Retrospective Studies | 41 | 2023 | 12975 | 1.310 |
Why?
| Brain Injuries, Traumatic | 2 | 2023 | 318 | 1.290 |
Why?
| Rural Health Services | 8 | 2020 | 93 | 1.250 |
Why?
| Intensive Care Units | 5 | 2021 | 635 | 1.240 |
Why?
| Vitamins | 7 | 2021 | 158 | 1.240 |
Why?
| Aged, 80 and over | 28 | 2021 | 6561 | 1.210 |
Why?
| Adolescent | 56 | 2023 | 18479 | 1.210 |
Why?
| Physicians | 10 | 2023 | 793 | 1.190 |
Why?
| Medicaid | 4 | 2015 | 411 | 1.170 |
Why?
| Pneumonia | 5 | 2021 | 592 | 1.150 |
Why?
| Health Care Surveys | 17 | 2020 | 546 | 1.140 |
Why?
| Mass Screening | 7 | 2012 | 1052 | 1.120 |
Why?
| Nurse Practitioners | 4 | 2012 | 107 | 1.110 |
Why?
| Antibodies, Neutralizing | 6 | 2022 | 228 | 1.110 |
Why?
| Influenza Vaccines | 8 | 2023 | 500 | 1.070 |
Why?
| Rehabilitation Centers | 2 | 2015 | 34 | 1.050 |
Why?
| Referral and Consultation | 5 | 2016 | 648 | 1.040 |
Why?
| Stroke | 5 | 2022 | 1046 | 1.030 |
Why?
| Intubation, Intratracheal | 10 | 2023 | 226 | 1.020 |
Why?
| Young Adult | 37 | 2023 | 10793 | 1.020 |
Why?
| Insurance, Health | 5 | 2020 | 244 | 0.990 |
Why?
| Diabetes Mellitus | 6 | 2011 | 942 | 0.970 |
Why?
| Shock, Traumatic | 1 | 2023 | 18 | 0.910 |
Why?
| Medically Uninsured | 3 | 2014 | 125 | 0.900 |
Why?
| Military Personnel | 4 | 2023 | 529 | 0.860 |
Why?
| Potentially Inappropriate Medication List | 1 | 2022 | 14 | 0.860 |
Why?
| Minority Groups | 2 | 2023 | 237 | 0.850 |
Why?
| Antiviral Agents | 6 | 2023 | 654 | 0.830 |
Why?
| Health Services Needs and Demand | 3 | 2013 | 254 | 0.830 |
Why?
| Airway Management | 1 | 2022 | 63 | 0.830 |
Why?
| Inappropriate Prescribing | 1 | 2022 | 51 | 0.830 |
Why?
| Internship and Residency | 8 | 2023 | 1001 | 0.820 |
Why?
| Treatment Outcome | 24 | 2023 | 9342 | 0.800 |
Why?
| Primary Health Care | 6 | 2019 | 1560 | 0.800 |
Why?
| Asthma | 11 | 2012 | 2157 | 0.800 |
Why?
| Pneumonia, Viral | 6 | 2020 | 348 | 0.780 |
Why?
| Coronavirus Infections | 6 | 2020 | 339 | 0.780 |
Why?
| Patient Outcome Assessment | 2 | 2021 | 122 | 0.770 |
Why?
| Critical Care | 5 | 2022 | 492 | 0.750 |
Why?
| Substance Abuse Detection | 1 | 2021 | 63 | 0.750 |
Why?
| Career Choice | 3 | 2010 | 192 | 0.730 |
Why?
| Pandemics | 11 | 2023 | 1354 | 0.720 |
Why?
| Tracheostomy | 1 | 2021 | 102 | 0.720 |
Why?
| Antibodies, Monoclonal | 6 | 2022 | 1284 | 0.720 |
Why?
| Resuscitation Orders | 2 | 2019 | 40 | 0.720 |
Why?
| Personnel Selection | 2 | 2010 | 71 | 0.710 |
Why?
| Age Factors | 12 | 2019 | 2995 | 0.710 |
Why?
| Spine | 1 | 2021 | 144 | 0.690 |
Why?
| Translating | 2 | 2010 | 35 | 0.690 |
Why?
| Warfare | 1 | 2019 | 77 | 0.680 |
Why?
| Resuscitation | 1 | 2021 | 253 | 0.660 |
Why?
| Triage | 3 | 2020 | 203 | 0.660 |
Why?
| Conservative Treatment | 1 | 2018 | 31 | 0.650 |
Why?
| Communication Barriers | 2 | 2010 | 94 | 0.650 |
Why?
| Oxygen Inhalation Therapy | 1 | 2019 | 124 | 0.650 |
Why?
| Brain Ischemia | 3 | 2021 | 309 | 0.620 |
Why?
| Health Surveys | 4 | 2014 | 454 | 0.620 |
Why?
| Brain Injuries | 1 | 2023 | 484 | 0.620 |
Why?
| Prospective Studies | 17 | 2023 | 6471 | 0.610 |
Why?
| Randomized Controlled Trials as Topic | 12 | 2023 | 1244 | 0.600 |
Why?
| Sex Factors | 10 | 2019 | 1781 | 0.600 |
Why?
| Guideline Adherence | 6 | 2022 | 523 | 0.600 |
Why?
| Surgical Procedures, Operative | 2 | 2016 | 215 | 0.590 |
Why?
| Professional Autonomy | 2 | 2014 | 25 | 0.580 |
Why?
| Interdisciplinary Studies | 1 | 2016 | 26 | 0.580 |
Why?
| Obesity | 4 | 2022 | 2746 | 0.580 |
Why?
| Financing, Organized | 1 | 2016 | 34 | 0.580 |
Why?
| Language | 2 | 2010 | 271 | 0.580 |
Why?
| Hydroxychloroquine | 3 | 2022 | 59 | 0.580 |
Why?
| Databases, Factual | 10 | 2021 | 1231 | 0.580 |
Why?
| Skilled Nursing Facilities | 2 | 2016 | 122 | 0.570 |
Why?
| Orthopedics | 1 | 2018 | 132 | 0.570 |
Why?
| MicroRNAs | 3 | 2017 | 637 | 0.560 |
Why?
| Healthcare Disparities | 3 | 2012 | 496 | 0.560 |
Why?
| Anti-Infective Agents | 2 | 2022 | 227 | 0.560 |
Why?
| Home Care Services | 2 | 2016 | 217 | 0.560 |
Why?
| Communication | 2 | 2014 | 761 | 0.550 |
Why?
| Vaccination | 11 | 2023 | 1222 | 0.540 |
Why?
| Pilot Projects | 7 | 2023 | 1419 | 0.540 |
Why?
| Acute Disease | 9 | 2020 | 940 | 0.540 |
Why?
| Boston | 8 | 2010 | 76 | 0.530 |
Why?
| Multiple Trauma | 1 | 2016 | 97 | 0.530 |
Why?
| Emergencies | 3 | 2015 | 153 | 0.530 |
Why?
| Cross Infection | 2 | 2020 | 205 | 0.520 |
Why?
| Insurance Coverage | 3 | 2016 | 208 | 0.520 |
Why?
| Homes for the Aged | 1 | 2015 | 19 | 0.520 |
Why?
| Hyperglycemia | 2 | 2009 | 312 | 0.510 |
Why?
| Antibodies, Viral | 4 | 2023 | 542 | 0.510 |
Why?
| Catheterization, Central Venous | 1 | 2016 | 95 | 0.510 |
Why?
| Severity of Illness Index | 11 | 2022 | 2674 | 0.510 |
Why?
| Halfway Houses | 1 | 2014 | 2 | 0.500 |
Why?
| Double-Blind Method | 12 | 2023 | 1687 | 0.500 |
Why?
| Shock, Septic | 4 | 2018 | 187 | 0.500 |
Why?
| Faculty, Medical | 1 | 2016 | 252 | 0.480 |
Why?
| Nutrition Surveys | 6 | 2011 | 233 | 0.480 |
Why?
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 75 | 0.480 |
Why?
| Patient Compliance | 3 | 2008 | 537 | 0.480 |
Why?
| Opioid-Related Disorders | 1 | 2021 | 417 | 0.470 |
Why?
| Hospitals, Rural | 2 | 2010 | 29 | 0.470 |
Why?
| Dietary Supplements | 6 | 2021 | 467 | 0.460 |
Why?
| Adenosine Monophosphate | 3 | 2021 | 51 | 0.460 |
Why?
| Hypoglycemia | 2 | 2008 | 400 | 0.460 |
Why?
| Point-of-Care Systems | 3 | 2011 | 151 | 0.460 |
Why?
| Analgesics, Opioid | 1 | 2021 | 793 | 0.460 |
Why?
| Urban Health Services | 5 | 2020 | 60 | 0.460 |
Why?
| Alanine | 3 | 2021 | 102 | 0.450 |
Why?
| Betacoronavirus | 3 | 2020 | 254 | 0.450 |
Why?
| Risk Factors | 13 | 2021 | 8999 | 0.450 |
Why?
| Surveys and Questionnaires | 9 | 2017 | 4708 | 0.450 |
Why?
| Antibodies, Monoclonal, Humanized | 3 | 2022 | 667 | 0.450 |
Why?
| California | 5 | 2019 | 382 | 0.450 |
Why?
| Medicare | 3 | 2015 | 663 | 0.440 |
Why?
| International Educational Exchange | 1 | 2012 | 11 | 0.440 |
Why?
| Renal Dialysis | 1 | 2016 | 378 | 0.430 |
Why?
| Inflammatory Bowel Diseases | 1 | 2017 | 290 | 0.430 |
Why?
| International Classification of Diseases | 2 | 2014 | 122 | 0.430 |
Why?
| Odds Ratio | 6 | 2018 | 996 | 0.420 |
Why?
| Oximetry | 2 | 2023 | 84 | 0.420 |
Why?
| Health Resources | 1 | 2013 | 132 | 0.420 |
Why?
| Treatment Failure | 6 | 2022 | 341 | 0.420 |
Why?
| Hospital Units | 1 | 2011 | 24 | 0.410 |
Why?
| Patient Education as Topic | 4 | 2010 | 699 | 0.410 |
Why?
| Observation | 1 | 2011 | 50 | 0.410 |
Why?
| Tomography, X-Ray Computed | 3 | 2017 | 2436 | 0.410 |
Why?
| Acute Kidney Injury | 3 | 2018 | 709 | 0.410 |
Why?
| Multivariate Analysis | 6 | 2016 | 1474 | 0.410 |
Why?
| Ambulatory Care | 5 | 2023 | 482 | 0.400 |
Why?
| Appointments and Schedules | 1 | 2011 | 78 | 0.400 |
Why?
| Liability, Legal | 1 | 2011 | 39 | 0.400 |
Why?
| Hyperparathyroidism, Secondary | 1 | 2011 | 10 | 0.400 |
Why?
| Logistic Models | 7 | 2021 | 1901 | 0.400 |
Why?
| Malpractice | 1 | 2011 | 38 | 0.400 |
Why?
| Patient Safety | 2 | 2016 | 281 | 0.400 |
Why?
| Inpatients | 2 | 2021 | 388 | 0.400 |
Why?
| Time Factors | 14 | 2023 | 6412 | 0.390 |
Why?
| Inflammation Mediators | 1 | 2014 | 502 | 0.390 |
Why?
| Colorado | 8 | 2023 | 4196 | 0.390 |
Why?
| Training Support | 1 | 2010 | 24 | 0.390 |
Why?
| Health Care Rationing | 1 | 2010 | 48 | 0.380 |
Why?
| Multicenter Studies as Topic | 5 | 2023 | 253 | 0.380 |
Why?
| Blood Glucose | 3 | 2008 | 1939 | 0.380 |
Why?
| Parathyroid Hormone | 1 | 2011 | 99 | 0.380 |
Why?
| Personnel, Hospital | 2 | 2020 | 23 | 0.380 |
Why?
| Cohort Studies | 13 | 2023 | 5115 | 0.370 |
Why?
| Military Medicine | 2 | 2022 | 94 | 0.370 |
Why?
| Digital Rectal Examination | 1 | 2010 | 10 | 0.370 |
Why?
| Occult Blood | 1 | 2010 | 27 | 0.370 |
Why?
| Inflammation | 1 | 2021 | 2566 | 0.360 |
Why?
| Patient Care | 1 | 2010 | 105 | 0.360 |
Why?
| Electronic Health Records | 3 | 2023 | 829 | 0.360 |
Why?
| Ambulances | 3 | 2023 | 49 | 0.360 |
Why?
| Risk Assessment | 8 | 2021 | 3057 | 0.350 |
Why?
| Child | 21 | 2022 | 19129 | 0.350 |
Why?
| Intrauterine Devices | 1 | 2009 | 24 | 0.350 |
Why?
| Cause of Death | 2 | 2017 | 380 | 0.330 |
Why?
| Body Mass Index | 4 | 2019 | 2092 | 0.330 |
Why?
| Socioeconomic Factors | 5 | 2015 | 1129 | 0.330 |
Why?
| South Africa | 3 | 2023 | 163 | 0.320 |
Why?
| Atracurium | 2 | 2019 | 13 | 0.320 |
Why?
| Neuromuscular Blocking Agents | 2 | 2019 | 23 | 0.320 |
Why?
| Mathematics | 1 | 2008 | 103 | 0.320 |
Why?
| Disease Models, Animal | 1 | 2017 | 3730 | 0.300 |
Why?
| Health Knowledge, Attitudes, Practice | 3 | 2015 | 1185 | 0.300 |
Why?
| Magnetic Resonance Imaging | 2 | 2008 | 3174 | 0.290 |
Why?
| Age Distribution | 4 | 2014 | 362 | 0.290 |
Why?
| Decision Support Systems, Clinical | 2 | 2021 | 178 | 0.290 |
Why?
| Acute Lung Injury | 2 | 2022 | 310 | 0.280 |
Why?
| Ivermectin | 2 | 2023 | 10 | 0.280 |
Why?
| Prevalence | 6 | 2014 | 2326 | 0.280 |
Why?
| Community-Acquired Infections | 2 | 2020 | 143 | 0.280 |
Why?
| Influenza A Virus, H3N2 Subtype | 2 | 2023 | 39 | 0.270 |
Why?
| Data Collection | 4 | 2014 | 658 | 0.270 |
Why?
| Cognitive Dysfunction | 2 | 2021 | 301 | 0.270 |
Why?
| Pulmonary Disease, Chronic Obstructive | 3 | 2009 | 1136 | 0.270 |
Why?
| Emergency Treatment | 3 | 2019 | 110 | 0.270 |
Why?
| Case-Control Studies | 9 | 2022 | 3171 | 0.260 |
Why?
| Staphylococcal Infections | 1 | 2009 | 346 | 0.260 |
Why?
| Pregnancy Complications | 1 | 2010 | 448 | 0.260 |
Why?
| Hospitals, Urban | 3 | 2016 | 129 | 0.250 |
Why?
| Vaccines, Synthetic | 5 | 2022 | 128 | 0.250 |
Why?
| Child, Preschool | 12 | 2019 | 9491 | 0.250 |
Why?
| Calcitriol | 2 | 2014 | 55 | 0.250 |
Why?
| Fluid Therapy | 2 | 2023 | 131 | 0.240 |
Why?
| Choice Behavior | 2 | 2019 | 160 | 0.240 |
Why?
| Medical Audit | 2 | 2018 | 75 | 0.240 |
Why?
| Disease Progression | 5 | 2021 | 2490 | 0.240 |
Why?
| Diabetic Ketoacidosis | 1 | 2006 | 168 | 0.240 |
Why?
| Physician-Patient Relations | 1 | 2009 | 489 | 0.240 |
Why?
| Ambulatory Care Facilities | 3 | 2020 | 218 | 0.240 |
Why?
| Chronic Disease | 3 | 2022 | 1636 | 0.240 |
Why?
| Patient Acceptance of Health Care | 2 | 2020 | 687 | 0.240 |
Why?
| Organ Dysfunction Scores | 2 | 2020 | 39 | 0.240 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2023 | 22 | 0.230 |
Why?
| Hypotension | 2 | 2023 | 120 | 0.230 |
Why?
| Attitude of Health Personnel | 1 | 2010 | 992 | 0.230 |
Why?
| Androstadienes | 1 | 2023 | 94 | 0.230 |
Why?
| RNA, Messenger | 7 | 2023 | 2657 | 0.230 |
Why?
| Comorbidity | 4 | 2021 | 1526 | 0.230 |
Why?
| Electronics | 1 | 2023 | 76 | 0.220 |
Why?
| Immunocompromised Host | 2 | 2022 | 200 | 0.220 |
Why?
| Lopinavir | 1 | 2022 | 29 | 0.220 |
Why?
| Respiratory Syncytial Virus, Human | 1 | 2023 | 61 | 0.220 |
Why?
| Urinary Tract Infections | 1 | 2004 | 136 | 0.220 |
Why?
| Renin-Angiotensin System | 1 | 2023 | 82 | 0.220 |
Why?
| Delirium | 1 | 2023 | 70 | 0.220 |
Why?
| Recovery of Function | 3 | 2022 | 604 | 0.220 |
Why?
| Respiratory Syncytial Virus Infections | 1 | 2023 | 99 | 0.210 |
Why?
| Syncope | 1 | 2022 | 32 | 0.210 |
Why?
| Cytokines | 2 | 2014 | 1900 | 0.210 |
Why?
| Health Services Research | 2 | 2016 | 385 | 0.210 |
Why?
| Vasoconstrictor Agents | 2 | 2023 | 122 | 0.210 |
Why?
| Immunization, Secondary | 1 | 2022 | 85 | 0.210 |
Why?
| Biomarkers | 7 | 2021 | 3588 | 0.200 |
Why?
| Positive-Pressure Respiration | 2 | 2019 | 70 | 0.200 |
Why?
| Veterans Health | 1 | 2023 | 167 | 0.200 |
Why?
| Rural Population | 3 | 2016 | 452 | 0.200 |
Why?
| Polypharmacy | 1 | 2022 | 75 | 0.200 |
Why?
| Incidence | 3 | 2019 | 2424 | 0.200 |
Why?
| Long Term Adverse Effects | 1 | 2021 | 10 | 0.200 |
Why?
| Malawi | 1 | 2021 | 50 | 0.200 |
Why?
| Hypoxia | 3 | 2023 | 963 | 0.200 |
Why?
| Abdominal Pain | 1 | 2022 | 133 | 0.200 |
Why?
| Academic Medical Centers | 4 | 2020 | 422 | 0.200 |
Why?
| Immunization Programs | 1 | 2023 | 206 | 0.200 |
Why?
| Drug Prescriptions | 1 | 2003 | 248 | 0.200 |
Why?
| Wounds, Penetrating | 1 | 2022 | 77 | 0.190 |
Why?
| Bayes Theorem | 1 | 2022 | 344 | 0.190 |
Why?
| Work | 1 | 2020 | 18 | 0.190 |
Why?
| Vasodilator Agents | 1 | 2023 | 328 | 0.190 |
Why?
| Quality of Health Care | 3 | 2010 | 586 | 0.190 |
Why?
| Telecommunications | 1 | 2020 | 17 | 0.190 |
Why?
| Contact Tracing | 1 | 2020 | 16 | 0.190 |
Why?
| Aftercare | 1 | 2022 | 194 | 0.190 |
Why?
| Neuromuscular Blockade | 2 | 2019 | 23 | 0.190 |
Why?
| Seasons | 4 | 2023 | 461 | 0.190 |
Why?
| Personnel Turnover | 2 | 2010 | 27 | 0.190 |
Why?
| Infant | 7 | 2019 | 8293 | 0.190 |
Why?
| Adrenergic beta-Agonists | 2 | 2012 | 132 | 0.190 |
Why?
| Video Recording | 4 | 2023 | 156 | 0.190 |
Why?
| Influenza A Virus, H1N1 Subtype | 1 | 2021 | 140 | 0.180 |
Why?
| Abbreviated Injury Scale | 1 | 2019 | 21 | 0.180 |
Why?
| Electrocardiography | 1 | 2003 | 556 | 0.180 |
Why?
| Physical Therapy Modalities | 1 | 2023 | 274 | 0.180 |
Why?
| Chi-Square Distribution | 3 | 2012 | 525 | 0.180 |
Why?
| Organ Transplantation | 1 | 2022 | 165 | 0.180 |
Why?
| Outpatient Clinics, Hospital | 1 | 2020 | 79 | 0.180 |
Why?
| Symptom Assessment | 1 | 2020 | 123 | 0.180 |
Why?
| Respiratory Insufficiency | 1 | 2023 | 290 | 0.180 |
Why?
| Iraq | 1 | 2019 | 82 | 0.180 |
Why?
| Continuity of Patient Care | 2 | 2012 | 265 | 0.170 |
Why?
| Agkistrodon | 1 | 2019 | 19 | 0.170 |
Why?
| Crotalid Venoms | 1 | 2019 | 31 | 0.170 |
Why?
| Dantrolene | 1 | 2019 | 5 | 0.170 |
Why?
| Afghanistan | 1 | 2019 | 108 | 0.170 |
Why?
| Immunoglobulin Fab Fragments | 1 | 2019 | 69 | 0.170 |
Why?
| Neuromuscular Depolarizing Agents | 1 | 2019 | 4 | 0.170 |
Why?
| Adrenal Cortex Hormones | 5 | 2021 | 521 | 0.170 |
Why?
| Malignant Hyperthermia | 1 | 2019 | 7 | 0.170 |
Why?
| Succinylcholine | 1 | 2019 | 6 | 0.170 |
Why?
| Muscle Relaxants, Central | 1 | 2019 | 10 | 0.170 |
Why?
| Dose-Response Relationship, Drug | 3 | 2020 | 1945 | 0.170 |
Why?
| Antivenins | 1 | 2019 | 54 | 0.170 |
Why?
| Lactic Acid | 1 | 2020 | 282 | 0.170 |
Why?
| Iraq War, 2003-2011 | 1 | 2019 | 151 | 0.170 |
Why?
| Consensus | 1 | 2021 | 534 | 0.170 |
Why?
| Needs Assessment | 3 | 2010 | 327 | 0.170 |
Why?
| Quality Indicators, Health Care | 2 | 2012 | 295 | 0.170 |
Why?
| Snake Bites | 1 | 2019 | 53 | 0.170 |
Why?
| Afghan Campaign 2001- | 1 | 2019 | 161 | 0.170 |
Why?
| Formative Feedback | 1 | 2018 | 22 | 0.160 |
Why?
| Injury Severity Score | 2 | 2022 | 528 | 0.160 |
Why?
| Platelet-Rich Plasma | 1 | 2018 | 29 | 0.160 |
Why?
| Out-of-Hospital Cardiac Arrest | 1 | 2019 | 79 | 0.160 |
Why?
| Time-to-Treatment | 4 | 2021 | 149 | 0.160 |
Why?
| Survivors | 1 | 2021 | 418 | 0.160 |
Why?
| Biological Specimen Banks | 1 | 2018 | 104 | 0.160 |
Why?
| Hospitals, Teaching | 2 | 2011 | 104 | 0.160 |
Why?
| Vaccines | 1 | 2023 | 380 | 0.160 |
Why?
| Clinical Competence | 2 | 2010 | 951 | 0.150 |
Why?
| Maryland | 1 | 2017 | 36 | 0.150 |
Why?
| Cardiovascular Diseases | 1 | 2009 | 1798 | 0.150 |
Why?
| Specimen Handling | 1 | 2018 | 165 | 0.150 |
Why?
| Cognition | 2 | 2023 | 1024 | 0.150 |
Why?
| Income | 2 | 2008 | 173 | 0.150 |
Why?
| Certification | 3 | 2020 | 99 | 0.150 |
Why?
| Civil Defense | 1 | 2017 | 20 | 0.150 |
Why?
| Oxygen Consumption | 1 | 2019 | 586 | 0.150 |
Why?
| Assisted Living Facilities | 1 | 2016 | 10 | 0.150 |
Why?
| Accidental Falls | 2 | 2016 | 154 | 0.140 |
Why?
| Executive Function | 1 | 2021 | 391 | 0.140 |
Why?
| Environmental Exposure | 1 | 2020 | 405 | 0.140 |
Why?
| Fibroblast Growth Factors | 1 | 2018 | 175 | 0.140 |
Why?
| Trachea | 3 | 2023 | 226 | 0.140 |
Why?
| Avalanches | 1 | 2016 | 3 | 0.140 |
Why?
| Educational Status | 2 | 2008 | 437 | 0.140 |
Why?
| Mountaineering | 1 | 2016 | 47 | 0.140 |
Why?
| Orthopedic Procedures | 1 | 2018 | 225 | 0.140 |
Why?
| Anesthesiology | 1 | 2016 | 39 | 0.130 |
Why?
| Advance Directives | 1 | 2016 | 62 | 0.130 |
Why?
| Colitis, Ulcerative | 1 | 2017 | 105 | 0.130 |
Why?
| Registries | 2 | 2022 | 1810 | 0.130 |
Why?
| Predictive Value of Tests | 3 | 2020 | 1868 | 0.130 |
Why?
| Urban Population | 3 | 2010 | 409 | 0.130 |
Why?
| AIDS Serodiagnosis | 2 | 2012 | 29 | 0.130 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2023 | 765 | 0.130 |
Why?
| Efficiency, Organizational | 1 | 2016 | 126 | 0.130 |
Why?
| Awareness | 1 | 2015 | 93 | 0.130 |
Why?
| Pulmonary Embolism | 1 | 2017 | 183 | 0.130 |
Why?
| Infant, Newborn | 3 | 2014 | 5255 | 0.130 |
Why?
| Evidence-Based Medicine | 2 | 2016 | 693 | 0.130 |
Why?
| Precision Medicine | 1 | 2018 | 363 | 0.130 |
Why?
| Perioperative Care | 1 | 2016 | 132 | 0.130 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 190 | 0.130 |
Why?
| Cost-Benefit Analysis | 1 | 2017 | 554 | 0.120 |
Why?
| Frail Elderly | 1 | 2015 | 107 | 0.120 |
Why?
| Neoplasms | 1 | 2008 | 2179 | 0.120 |
Why?
| Hepatopulmonary Syndrome | 1 | 2014 | 26 | 0.120 |
Why?
| Creatinine | 1 | 2015 | 491 | 0.120 |
Why?
| Confidence Intervals | 3 | 2010 | 324 | 0.120 |
Why?
| Health Care Costs | 1 | 2017 | 394 | 0.120 |
Why?
| Fluvoxamine | 2 | 2023 | 13 | 0.120 |
Why?
| Quality Improvement | 1 | 2021 | 963 | 0.120 |
Why?
| Crohn Disease | 1 | 2017 | 197 | 0.120 |
Why?
| Lipopolysaccharides | 1 | 2017 | 870 | 0.120 |
Why?
| Patient-Centered Care | 2 | 2016 | 497 | 0.110 |
Why?
| Risk | 2 | 2017 | 853 | 0.110 |
Why?
| Delivery of Health Care | 1 | 2020 | 867 | 0.110 |
Why?
| Pneumonia, Bacterial | 1 | 2014 | 110 | 0.110 |
Why?
| Vaccines, Combined | 2 | 2022 | 46 | 0.110 |
Why?
| Headache | 1 | 2013 | 128 | 0.110 |
Why?
| Physician's Role | 1 | 2014 | 200 | 0.110 |
Why?
| Preventive Health Services | 2 | 2012 | 135 | 0.110 |
Why?
| Hospital Costs | 1 | 2013 | 110 | 0.110 |
Why?
| Anti-Bacterial Agents | 4 | 2018 | 1510 | 0.110 |
Why?
| Sampling Studies | 1 | 2012 | 92 | 0.100 |
Why?
| Oregon | 1 | 2011 | 69 | 0.100 |
Why?
| Immune System | 1 | 2013 | 181 | 0.100 |
Why?
| Georgia | 1 | 2011 | 61 | 0.100 |
Why?
| Combined Modality Therapy | 2 | 2019 | 1166 | 0.100 |
Why?
| Neutrophils | 1 | 2017 | 1233 | 0.100 |
Why?
| Epithelial Cells | 1 | 2017 | 963 | 0.100 |
Why?
| Sex Distribution | 2 | 2013 | 351 | 0.100 |
Why?
| Massachusetts | 1 | 2011 | 141 | 0.100 |
Why?
| Fractures, Bone | 1 | 2016 | 380 | 0.100 |
Why?
| HIV | 1 | 2012 | 210 | 0.100 |
Why?
| Drug Administration Schedule | 3 | 2019 | 736 | 0.100 |
Why?
| Professional Practice Location | 1 | 2010 | 26 | 0.100 |
Why?
| Specialization | 1 | 2011 | 120 | 0.100 |
Why?
| Mice, Inbred C57BL | 2 | 2017 | 4908 | 0.100 |
Why?
| Viral Load | 2 | 2023 | 419 | 0.100 |
Why?
| Statistics, Nonparametric | 2 | 2009 | 403 | 0.100 |
Why?
| Mice, Knockout | 1 | 2017 | 2680 | 0.100 |
Why?
| Patient Protection and Affordable Care Act | 1 | 2011 | 102 | 0.090 |
Why?
| Workload | 1 | 2011 | 128 | 0.090 |
Why?
| Legislation as Topic | 1 | 2010 | 4 | 0.090 |
Why?
| Delegation, Professional | 1 | 2010 | 1 | 0.090 |
Why?
| Health Care Reform | 1 | 2011 | 95 | 0.090 |
Why?
| Bias | 2 | 2021 | 198 | 0.090 |
Why?
| Medical Staff, Hospital | 1 | 2010 | 76 | 0.090 |
Why?
| Emergency Nursing | 1 | 2010 | 18 | 0.090 |
Why?
| Medically Underserved Area | 1 | 2010 | 87 | 0.090 |
Why?
| Occupations | 1 | 2010 | 37 | 0.090 |
Why?
| Altitude | 1 | 2014 | 422 | 0.090 |
Why?
| Social Class | 2 | 2009 | 218 | 0.090 |
Why?
| Quality of Life | 1 | 2021 | 2366 | 0.090 |
Why?
| Albuterol | 1 | 2010 | 104 | 0.090 |
Why?
| Infusions, Intravenous | 2 | 2023 | 380 | 0.090 |
Why?
| Allied Health Personnel | 1 | 2010 | 44 | 0.090 |
Why?
| Practice Patterns, Physicians' | 1 | 2018 | 1199 | 0.090 |
Why?
| Mental Health Services | 1 | 2014 | 331 | 0.090 |
Why?
| Motivation | 2 | 2012 | 506 | 0.090 |
Why?
| Medical Order Entry Systems | 1 | 2010 | 42 | 0.090 |
Why?
| Geriatric Assessment | 1 | 2011 | 185 | 0.090 |
Why?
| Sensitivity and Specificity | 1 | 2014 | 1795 | 0.090 |
Why?
| Algorithms | 1 | 2017 | 1541 | 0.090 |
Why?
| Interprofessional Relations | 1 | 2011 | 261 | 0.090 |
Why?
| Population | 1 | 2009 | 30 | 0.090 |
Why?
| RNA, Viral | 2 | 2023 | 572 | 0.090 |
Why?
| Specialty Boards | 1 | 2009 | 39 | 0.090 |
Why?
| Schools, Veterinary | 1 | 2008 | 2 | 0.080 |
Why?
| Job Satisfaction | 1 | 2010 | 175 | 0.080 |
Why?
| Self Report | 2 | 2023 | 699 | 0.080 |
Why?
| Nutritional Status | 1 | 2011 | 300 | 0.080 |
Why?
| Forced Expiratory Volume | 1 | 2010 | 520 | 0.080 |
Why?
| Respiratory Syncytial Viruses | 1 | 2008 | 48 | 0.080 |
Why?
| Insulin | 2 | 2009 | 2162 | 0.080 |
Why?
| Nurses | 1 | 2010 | 142 | 0.080 |
Why?
| Fatal Outcome | 1 | 2009 | 287 | 0.080 |
Why?
| Professional Role | 1 | 2010 | 153 | 0.080 |
Why?
| Smoking Cessation | 1 | 2012 | 360 | 0.080 |
Why?
| Disease Management | 2 | 2011 | 571 | 0.080 |
Why?
| Drug Therapy, Combination | 2 | 2021 | 965 | 0.080 |
Why?
| Interleukin-10 | 1 | 2010 | 306 | 0.080 |
Why?
| Device Removal | 1 | 2009 | 127 | 0.080 |
Why?
| Mexican Americans | 1 | 2009 | 100 | 0.080 |
Why?
| Mental Recall | 2 | 2021 | 180 | 0.080 |
Why?
| Glucocorticoids | 2 | 2023 | 545 | 0.080 |
Why?
| Feasibility Studies | 2 | 2023 | 749 | 0.080 |
Why?
| Immunity, Innate | 2 | 2014 | 745 | 0.080 |
Why?
| Statistics as Topic | 1 | 2008 | 307 | 0.080 |
Why?
| Animals | 4 | 2019 | 33381 | 0.080 |
Why?
| Health Status Indicators | 1 | 2008 | 154 | 0.080 |
Why?
| Morbidity | 1 | 2008 | 296 | 0.080 |
Why?
| Glucose Tolerance Test | 1 | 2008 | 368 | 0.070 |
Why?
| Data Interpretation, Statistical | 1 | 2009 | 336 | 0.070 |
Why?
| Clinical Trials as Topic | 2 | 2022 | 968 | 0.070 |
Why?
| Forecasting | 1 | 2008 | 353 | 0.070 |
Why?
| Administration, Inhalation | 2 | 2023 | 656 | 0.070 |
Why?
| RNA | 2 | 2023 | 833 | 0.070 |
Why?
| Liver Transplantation | 1 | 2014 | 847 | 0.070 |
Why?
| Virus Diseases | 1 | 2008 | 198 | 0.070 |
Why?
| Papillomavirus Vaccines | 1 | 2009 | 221 | 0.070 |
Why?
| Proportional Hazards Models | 1 | 2009 | 1125 | 0.070 |
Why?
| Geography | 1 | 2006 | 190 | 0.070 |
Why?
| Papillomavirus Infections | 1 | 2009 | 265 | 0.070 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2009 | 359 | 0.070 |
Why?
| History, 21st Century | 1 | 2006 | 170 | 0.070 |
Why?
| Self Care | 1 | 2008 | 357 | 0.070 |
Why?
| Staphylococcus aureus | 1 | 2009 | 394 | 0.070 |
Why?
| History, 20th Century | 1 | 2006 | 281 | 0.070 |
Why?
| Calcium | 1 | 2011 | 1169 | 0.060 |
Why?
| Analysis of Variance | 1 | 2008 | 1293 | 0.060 |
Why?
| Lung | 1 | 2017 | 3664 | 0.060 |
Why?
| Postoperative Complications | 1 | 2015 | 2235 | 0.060 |
Why?
| Missouri | 1 | 2004 | 63 | 0.060 |
Why?
| Prognosis | 2 | 2020 | 3443 | 0.060 |
Why?
| Patient Acuity | 1 | 2023 | 37 | 0.060 |
Why?
| Angiotensins | 1 | 2023 | 11 | 0.060 |
Why?
| Sex Characteristics | 1 | 2008 | 671 | 0.060 |
Why?
| Macrolides | 1 | 2003 | 57 | 0.060 |
Why?
| Calibration | 1 | 2023 | 135 | 0.060 |
Why?
| Remission Induction | 1 | 2023 | 247 | 0.060 |
Why?
| Drug Repositioning | 1 | 2022 | 14 | 0.060 |
Why?
| Nucleocapsid | 1 | 2022 | 17 | 0.060 |
Why?
| Angiotensin II | 1 | 2023 | 107 | 0.050 |
Why?
| Emergency Medical Dispatch | 1 | 2022 | 7 | 0.050 |
Why?
| Immunocompetence | 1 | 2022 | 43 | 0.050 |
Why?
| Medical Futility | 1 | 2021 | 22 | 0.050 |
Why?
| Influenza B virus | 1 | 2021 | 33 | 0.050 |
Why?
| Syndrome | 1 | 2022 | 344 | 0.050 |
Why?
| Information Systems | 1 | 2022 | 66 | 0.050 |
Why?
| Pulse Therapy, Drug | 1 | 2021 | 6 | 0.050 |
Why?
| Health Promotion | 2 | 2022 | 691 | 0.050 |
Why?
| Oligopeptides | 1 | 2023 | 252 | 0.050 |
Why?
| Ligands | 1 | 2023 | 567 | 0.050 |
Why?
| Immunization, Passive | 1 | 2021 | 81 | 0.050 |
Why?
| Antigens, Viral | 1 | 2021 | 181 | 0.050 |
Why?
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 5 | 0.050 |
Why?
| Intention to Treat Analysis | 1 | 2020 | 70 | 0.050 |
Why?
| HIV Infections | 2 | 2012 | 2459 | 0.050 |
Why?
| Transplant Recipients | 1 | 2022 | 148 | 0.050 |
Why?
| Antimalarials | 1 | 2020 | 24 | 0.050 |
Why?
| Personnel Staffing and Scheduling | 2 | 2011 | 81 | 0.050 |
Why?
| Hypoglycemic Agents | 1 | 2008 | 1032 | 0.050 |
Why?
| Immunization Schedule | 1 | 2022 | 188 | 0.050 |
Why?
| Immunization | 1 | 2023 | 412 | 0.050 |
Why?
| Vaccination Coverage | 1 | 2021 | 63 | 0.050 |
Why?
| Documentation | 1 | 2022 | 175 | 0.050 |
Why?
| Health Facilities | 1 | 2021 | 75 | 0.050 |
Why?
| Personal Protective Equipment | 1 | 2020 | 50 | 0.050 |
Why?
| Seroepidemiologic Studies | 1 | 2020 | 146 | 0.050 |
Why?
| Follow-Up Studies | 1 | 2009 | 4596 | 0.050 |
Why?
| Asymptomatic Diseases | 1 | 2020 | 81 | 0.050 |
Why?
| Single-Blind Method | 1 | 2020 | 269 | 0.040 |
Why?
| Recombinant Fusion Proteins | 1 | 2022 | 653 | 0.040 |
Why?
| Ergocalciferols | 1 | 2019 | 12 | 0.040 |
Why?
| ROC Curve | 1 | 2020 | 473 | 0.040 |
Why?
| Practice Guidelines as Topic | 2 | 2022 | 1440 | 0.040 |
Why?
| Education, Medical, Graduate | 1 | 2003 | 399 | 0.040 |
Why?
| Program Evaluation | 1 | 2003 | 845 | 0.040 |
Why?
| Conscious Sedation | 1 | 2019 | 79 | 0.040 |
Why?
| Host-Pathogen Interactions | 1 | 2021 | 300 | 0.040 |
Why?
| Renal Replacement Therapy | 1 | 2018 | 70 | 0.040 |
Why?
| RNA Transport | 1 | 2017 | 22 | 0.040 |
Why?
| Pregnancy | 1 | 2010 | 5691 | 0.040 |
Why?
| Informed Consent | 1 | 2018 | 163 | 0.040 |
Why?
| Controlled Before-After Studies | 1 | 2017 | 16 | 0.040 |
Why?
| Workflow | 1 | 2018 | 148 | 0.040 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 87 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2019 | 842 | 0.040 |
Why?
| Africa | 1 | 2017 | 100 | 0.040 |
Why?
| Historically Controlled Study | 1 | 2016 | 5 | 0.040 |
Why?
| Gene Knockdown Techniques | 1 | 2017 | 311 | 0.040 |
Why?
| Neuropsychological Tests | 1 | 2021 | 1032 | 0.040 |
Why?
| Ghana | 1 | 2015 | 30 | 0.030 |
Why?
| Cell Communication | 1 | 2017 | 281 | 0.030 |
Why?
| Depression | 1 | 2023 | 1132 | 0.030 |
Why?
| Reimbursement, Incentive | 1 | 2015 | 38 | 0.030 |
Why?
| Cathelicidins | 1 | 2014 | 39 | 0.030 |
Why?
| Mortality | 1 | 2017 | 299 | 0.030 |
Why?
| Qualitative Research | 1 | 2019 | 953 | 0.030 |
Why?
| Injections, Intravenous | 1 | 2014 | 210 | 0.030 |
Why?
| Muscle Strength | 1 | 2017 | 283 | 0.030 |
Why?
| Antimicrobial Cationic Peptides | 1 | 2014 | 78 | 0.030 |
Why?
| Clinical Coding | 1 | 2013 | 23 | 0.030 |
Why?
| Nanoparticles | 1 | 2017 | 325 | 0.030 |
Why?
| Internet | 1 | 2017 | 633 | 0.030 |
Why?
| Research Design | 1 | 2018 | 969 | 0.030 |
Why?
| Bed Occupancy | 1 | 2011 | 11 | 0.030 |
Why?
| Domestic Violence | 1 | 2011 | 45 | 0.020 |
Why?
| Resource Allocation | 1 | 2010 | 38 | 0.020 |
Why?
| Salmeterol Xinafoate | 1 | 2010 | 42 | 0.020 |
Why?
| Pamphlets | 1 | 2010 | 25 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2017 | 2513 | 0.020 |
Why?
| Demography | 1 | 2010 | 274 | 0.020 |
Why?
| Tobacco Use Disorder | 1 | 2012 | 233 | 0.020 |
Why?
| Consumer Health Information | 1 | 2010 | 48 | 0.020 |
Why?
| Self Efficacy | 1 | 2012 | 366 | 0.020 |
Why?
| Psychometrics | 1 | 2012 | 631 | 0.020 |
Why?
| Patient Satisfaction | 1 | 2012 | 610 | 0.020 |
Why?
| Teaching | 1 | 2010 | 236 | 0.020 |
Why?
| Research | 1 | 2011 | 411 | 0.020 |
Why?
| Linear Models | 1 | 2009 | 827 | 0.020 |
Why?
| Anti-Asthmatic Agents | 1 | 2010 | 343 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2012 | 2874 | 0.020 |
Why?
|
|
Ginde's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|